Open-label memantine in fragile X syndrome

Craig A. Erickson, Jennifer E. Mullett, Christopher J. McDougle

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed. Six patients received memantine over a mean 34.7 weeks of treatment. Four of 6 (67%) patients showed global clinical benefit on ratings with the CGI-I. Symptom specific rating scales, however, showed no statistically significant improvement. Two patient developed treatment-limiting irritability on memantine. Memantine was modestly effective in several patients with FXS. Further systematic study is warranted.

Original languageEnglish
Pages (from-to)1629-1635
Number of pages7
JournalJournal of Autism and Developmental Disorders
Volume39
Issue number12
DOIs
StatePublished - Dec 2009

Fingerprint

Memantine
Fragile X Syndrome
Medical Records
Therapeutics

Keywords

  • Fragile X syndrome
  • Hyperactivity
  • Inattention
  • Irritability
  • Memantine
  • Social withdrawal

ASJC Scopus subject areas

  • Developmental and Educational Psychology

Cite this

Open-label memantine in fragile X syndrome. / Erickson, Craig A.; Mullett, Jennifer E.; McDougle, Christopher J.

In: Journal of Autism and Developmental Disorders, Vol. 39, No. 12, 12.2009, p. 1629-1635.

Research output: Contribution to journalArticle

Erickson, Craig A. ; Mullett, Jennifer E. ; McDougle, Christopher J. / Open-label memantine in fragile X syndrome. In: Journal of Autism and Developmental Disorders. 2009 ; Vol. 39, No. 12. pp. 1629-1635.
@article{a5e92769439848e48835f4ecae0a0f31,
title = "Open-label memantine in fragile X syndrome",
abstract = "Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed. Six patients received memantine over a mean 34.7 weeks of treatment. Four of 6 (67{\%}) patients showed global clinical benefit on ratings with the CGI-I. Symptom specific rating scales, however, showed no statistically significant improvement. Two patient developed treatment-limiting irritability on memantine. Memantine was modestly effective in several patients with FXS. Further systematic study is warranted.",
keywords = "Fragile X syndrome, Hyperactivity, Inattention, Irritability, Memantine, Social withdrawal",
author = "Erickson, {Craig A.} and Mullett, {Jennifer E.} and McDougle, {Christopher J.}",
year = "2009",
month = "12",
doi = "10.1007/s10803-009-0807-3",
language = "English",
volume = "39",
pages = "1629--1635",
journal = "Journal of Autism and Developmental Disorders",
issn = "0162-3257",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Open-label memantine in fragile X syndrome

AU - Erickson, Craig A.

AU - Mullett, Jennifer E.

AU - McDougle, Christopher J.

PY - 2009/12

Y1 - 2009/12

N2 - Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed. Six patients received memantine over a mean 34.7 weeks of treatment. Four of 6 (67%) patients showed global clinical benefit on ratings with the CGI-I. Symptom specific rating scales, however, showed no statistically significant improvement. Two patient developed treatment-limiting irritability on memantine. Memantine was modestly effective in several patients with FXS. Further systematic study is warranted.

AB - Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed. Six patients received memantine over a mean 34.7 weeks of treatment. Four of 6 (67%) patients showed global clinical benefit on ratings with the CGI-I. Symptom specific rating scales, however, showed no statistically significant improvement. Two patient developed treatment-limiting irritability on memantine. Memantine was modestly effective in several patients with FXS. Further systematic study is warranted.

KW - Fragile X syndrome

KW - Hyperactivity

KW - Inattention

KW - Irritability

KW - Memantine

KW - Social withdrawal

UR - http://www.scopus.com/inward/record.url?scp=70450247105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450247105&partnerID=8YFLogxK

U2 - 10.1007/s10803-009-0807-3

DO - 10.1007/s10803-009-0807-3

M3 - Article

C2 - 19609663

AN - SCOPUS:70450247105

VL - 39

SP - 1629

EP - 1635

JO - Journal of Autism and Developmental Disorders

JF - Journal of Autism and Developmental Disorders

SN - 0162-3257

IS - 12

ER -